At 21.9% CAGR, Europe Human Microbiome Market is Projected to be Worth US$ 999.66 Million by 2031, says Business Market Insights

According to Business Market Insights research, the Europe human microbiome market was valued at US$ 204.79 million in 2023 and is expected to reach US$ 999.66 million by 2031, registering a CAGR of 21.9% from 2023 to 2031. Government initiatives and significant investments by key market players are among the critical factors attributed to drive the Europe human microbiome market growth.

Government initiatives and support programs significantly impact the human microbiome market growth. Governments frequently give large sums of money and grants for studies on the human microbiome. This financial assistance speeds up the development of novel treatments, devices, and diagnostics. Funding supports the innovation and commercialization of products by startups and small-to-medium-sized enterprises (SMEs) in the human microbiome sector. For instance, the project launched by NIH can transform understanding of human health and prevent, diagnose, and treat various conditions. Part of the NIH’s Roadmap for Medical Research, the Human Microbiome Project will award US$ 115 million to researchers over the next five years. Regulating frameworks tailored to human microbiome-based products may be established or improved by governments, which would shorten the time and expense involved in introducing novel treatments to the market. Well-defined regulations guarantee the safety and efficacy of products, thereby increasing consumer trust and market uptake.

Microbiome-based therapeutics is a booming field. The interest in microbiome-based therapies has increased due to the recent approval of Vowst, a medication from Seres Therapeutics, to treat C. difficile infections. Significant progress is being made in the European Union (EU) to reclassify vaginal probiotics as pharmaceutical drugs.

On the contrary, the challenges during production of microbiome hamper the growth of Europe human microbiome market.

Based on type, the Europe human microbiome market is bifurcated into product and software and services. The product segment held 61.1% market share in 2023, amassing US$ 125.17 million. It is projected to garner US$ 559.35 million by 2031 to register 20.6% CAGR during 2023–2031. The product segment is further sub segmented into probiotics and prebiotics.

By application, the Europe human microbiome market is segmented into herapeutics, diagnostics, and research. The therapeutics segment held 58.9% share of Europe human microbiome market in 2023, amassing US$ 120.59 million. It is anticipated to garner US$ 601.93 million by 2031 to expand at 22.3% CAGR during 2023–2031.

By disease type, the Europe human microbiome market is segmented into obesity, diabetes, autoimmune disorder, cancer, GIT, and others. The GIT segment held 36.9% market share in 2023, amassing US$ 75.61 million. It is projected to garner US$ 391.23 million by 2031 to register 22.8% CAGR during 2023–2031.

By country, the Europe human microbiome market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 21.3% share of Europe human microbiome market in 2023. It was assessed at US$ 43.52 million in 2023 and is likely to hit US$ 228.62 million by 2031, registering a CAGR of 23.0% during 2023–2031.

Key players operating in the human microbiome market are MaaT Pharma; Ferring Holdings SA; AOBiome Therapeutics Inc; Finch Therapeutics Group Inc; Seres Therapeutics Inc; Merck & Co Inc; Rebiotix, Inc.; Yakult Honsha Co., Ltd.; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc. among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com